Compounds useful as inhibitors of atr kinase

A compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein
• Ring D is isoxazolyl or oxadiazolyl;
• Ring A is a 5-6 membered monocyclic aryl or heteroaryl ring, wherein said heteroaryl ring has 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur;
• J is halo or C1-6alkyl, wherein 0-1 methylene units of said C1-6alkyl is replaced with —O—.
• J1 is halo or —(X)q—Y;
• X is C1-10alkyl wherein 0-2 methylene units of said C1-6alkyl are replaced with NR, O, or S;
• X is optionally substituted with 1-2 occurrences of C1-3alkyl or halo;
• Y is hydrogen, C1-4alkyl, or a 3-6 membered saturated or partially unsaturated cycloaliphatic or heterocyclyl, wherein said heterocyclyl has 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
• wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C1-3alkyl;
• or J and J1 join together to form a 5-7 heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
• wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or C1-3alkyl;
• wherein 0-1 methylene units of said C1-3alkyl is replaced with —O—, —NR—, —S—, or —CO—.
• p and q are each independently 0 or 1;
• J2 is H or C1-6alkyl;
• J3 is H or C1-6alkyl;
• or J2 and J3 join together to form a 3-7 membered monocyclic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
• or a 8-10 membered bicylic or bridged ring having 0-4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
• wherein said monocyclic, bicyclic, or bridged ring is optionally substituted with 1-2 occurrences of halo or C1-3alkyl;
• J4 is CN, OH, or L-Z;
• J5 is H or fluoro;
• L is C(O), S(O)2, or C(O)NR;
• Z is (U)t—Q or C1-6alkyl wherein 0-2 methylene units of said C1-6alkyl are replaced with O or NR;
• U is C1-2alkyl;
• t is 0 or 1;
• Q is C3-6cycloalkyl or 4-6 membered saturated or partially saturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
• and
• R is H or C1-4alkyl.